Titre : Éphrine A3

Éphrine A3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Vision Screening
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Éphrine A3 : Questions médicales les plus fréquentes", "headline": "Éphrine A3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Éphrine A3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-21", "dateModified": "2025-02-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Éphrine A3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Éphrines", "url": "https://questionsmedicales.fr/mesh/D036342", "about": { "@type": "MedicalCondition", "name": "Éphrines", "code": { "@type": "MedicalCode", "code": "D036342", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.500" } } }, "about": { "@type": "MedicalCondition", "name": "Éphrine A3", "alternateName": "Ephrin-A3", "code": { "@type": "MedicalCode", "code": "D036384", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Elena B Pasquale", "url": "https://questionsmedicales.fr/author/Elena%20B%20Pasquale", "affiliation": { "@type": "Organization", "name": "Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. elenap@sbpdiscovery.org." } }, { "@type": "Person", "name": "Katsuaki Ieguchi", "url": "https://questionsmedicales.fr/author/Katsuaki%20Ieguchi", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. kieguchi@twmu.ac.jp." } }, { "@type": "Person", "name": "Yoshiro Maru", "url": "https://questionsmedicales.fr/author/Yoshiro%20Maru", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. maru.yoshiro@twmu.ac.jp." } }, { "@type": "Person", "name": "Stamatios Theocharis", "url": "https://questionsmedicales.fr/author/Stamatios%20Theocharis", "affiliation": { "@type": "Organization", "name": "First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece." } }, { "@type": "Person", "name": "Liu Yang", "url": "https://questionsmedicales.fr/author/Liu%20Yang", "affiliation": { "@type": "Organization", "name": "Department of Ophthalmology, Peking University First Hospital, Beijing, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Manhattan Vision Screening and Follow-up Study (NYC-SIGHT): Baseline Results and Costs of a Cluster-Randomized Trial.", "datePublished": "2023-01-21", "url": "https://questionsmedicales.fr/article/36690289", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2023.01.019" } }, { "@type": "ScholarlyArticle", "name": "Missed Vision Screenings for School-Age Children During The COVID-19 Pandemic: A Survey Based Study of NASN Representatives.", "datePublished": "2022-08-02", "url": "https://questionsmedicales.fr/article/35915998", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/10598405221117511" } }, { "@type": "ScholarlyArticle", "name": "Survey on pattern of myopia in school children in Hangzhou after the COVID-19 pandemic: a school-based vision screening study.", "datePublished": "2024-07-11", "url": "https://questionsmedicales.fr/article/38992612", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12889-024-19338-4" } }, { "@type": "ScholarlyArticle", "name": "Race, poverty, and the lack of follow-up for Arkansas students that fail vision screenings: a cross-sectional study over 7 years.", "datePublished": "2023-05-05", "url": "https://questionsmedicales.fr/article/37150435", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jaapos.2023.02.005" } }, { "@type": "ScholarlyArticle", "name": "Prevalence of myopia and uncorrected myopia among 721 032 schoolchildren in a city-wide vision screening in southern China: the Shantou Myopia Study.", "datePublished": "2023-11-22", "url": "https://questionsmedicales.fr/article/36198476", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bjo-2021-320940" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Éphrines", "item": "https://questionsmedicales.fr/mesh/D036342" }, { "@type": "ListItem", "position": 5, "name": "Éphrine A3", "item": "https://questionsmedicales.fr/mesh/D036384" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Éphrine A3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Éphrine A3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Éphrine A3", "description": "Comment diagnostiquer une anomalie d'éphrine A3 ?\nQuels examens sont recommandés pour évaluer l'éphrine A3 ?\nY a-t-il des biomarqueurs associés à l'éphrine A3 ?\nQuels symptômes peuvent indiquer un problème avec l'éphrine A3 ?\nPeut-on utiliser l'imagerie pour évaluer l'éphrine A3 ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Vision+Screening&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Éphrine A3", "description": "Quels sont les symptômes d'une dysfonction d'éphrine A3 ?\nL'éphrine A3 est-elle liée à des maladies spécifiques ?\nComment l'éphrine A3 affecte-t-elle le système nerveux ?\nDes troubles comportementaux peuvent-ils être liés à l'éphrine A3 ?\nL'éphrine A3 influence-t-elle le développement cérébral ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Vision+Screening&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Éphrine A3", "description": "Peut-on prévenir les troubles liés à l'éphrine A3 ?\nY a-t-il des facteurs environnementaux influençant l'éphrine A3 ?\nComment le mode de vie affecte-t-il l'éphrine A3 ?\nDes conseils nutritionnels peuvent-ils aider ?\nL'éducation prénatale peut-elle prévenir des troubles ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Vision+Screening&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Éphrine A3", "description": "Quels traitements ciblent l'éphrine A3 ?\nPeut-on modifier l'expression de l'éphrine A3 ?\nY a-t-il des essais cliniques sur l'éphrine A3 ?\nQuels médicaments peuvent affecter l'éphrine A3 ?\nL'éphrine A3 peut-elle être une cible thérapeutique ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Vision+Screening&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Éphrine A3", "description": "Quelles complications peuvent survenir avec l'éphrine A3 ?\nL'éphrine A3 est-elle impliquée dans des cancers ?\nDes troubles cognitifs peuvent-ils être des complications ?\nComment les complications sont-elles gérées ?\nY a-t-il des risques de récidive avec l'éphrine A3 ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Vision+Screening&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Éphrine A3", "description": "Quels sont les facteurs de risque pour l'éphrine A3 ?\nL'hérédité joue-t-elle un rôle dans les troubles d'éphrine A3 ?\nLes toxines environnementales affectent-elles l'éphrine A3 ?\nLe stress peut-il influencer l'éphrine A3 ?\nY a-t-il des prédispositions génétiques pour l'éphrine A3 ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Vision+Screening&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie d'éphrine A3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de tissus peuvent être utilisés pour détecter des anomalies." } }, { "@type": "Question", "name": "Quels examens sont recommandés pour évaluer l'éphrine A3 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'immunohistochimie et la PCR sont souvent utilisés pour évaluer l'expression de l'éphrine A3." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à l'éphrine A3 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'éphrine A3 elle-même peut servir de biomarqueur dans certaines pathologies neurologiques." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec l'éphrine A3 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques ou des anomalies de développement peuvent indiquer un problème." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour évaluer l'éphrine A3 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie cérébrale peut aider à visualiser des anomalies associées à des dysfonctionnements de l'éphrine A3." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une dysfonction d'éphrine A3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des troubles cognitifs, des problèmes de coordination et des retards de développement." } }, { "@type": "Question", "name": "L'éphrine A3 est-elle liée à des maladies spécifiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies d'éphrine A3 sont associées à des maladies neurodégénératives et des cancers." } }, { "@type": "Question", "name": "Comment l'éphrine A3 affecte-t-elle le système nerveux ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elle joue un rôle dans la formation des synapses et la plasticité neuronale, influençant le comportement." } }, { "@type": "Question", "name": "Des troubles comportementaux peuvent-ils être liés à l'éphrine A3 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dysfonctionnements de l'éphrine A3 peuvent entraîner des troubles du comportement." } }, { "@type": "Question", "name": "L'éphrine A3 influence-t-elle le développement cérébral ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est essentielle pour le développement normal des circuits neuronaux dans le cerveau." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles liés à l'éphrine A3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par une détection précoce et une intervention dans les cas à risque." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux influençant l'éphrine A3 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs environnementaux comme la nutrition et les toxines peuvent influencer son expression." } }, { "@type": "Question", "name": "Comment le mode de vie affecte-t-il l'éphrine A3 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut favoriser une expression normale de l'éphrine A3 et réduire les risques." } }, { "@type": "Question", "name": "Des conseils nutritionnels peuvent-ils aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en nutriments peut soutenir la santé neuronale et l'éphrine A3." } }, { "@type": "Question", "name": "L'éducation prénatale peut-elle prévenir des troubles ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation prénatale sur les risques environnementaux peut aider à prévenir des troubles liés à l'éphrine A3." } }, { "@type": "Question", "name": "Quels traitements ciblent l'éphrine A3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des médicaments ciblant les voies de signalisation peuvent être envisagés." } }, { "@type": "Question", "name": "Peut-on modifier l'expression de l'éphrine A3 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des approches pharmacologiques peuvent moduler l'expression de l'éphrine A3 dans certaines conditions." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques sur l'éphrine A3 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des essais cliniques sont en cours pour évaluer des traitements ciblant l'éphrine A3 dans diverses pathologies." } }, { "@type": "Question", "name": "Quels médicaments peuvent affecter l'éphrine A3 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments anticancéreux et neuroprotecteurs peuvent influencer l'activité de l'éphrine A3." } }, { "@type": "Question", "name": "L'éphrine A3 peut-elle être une cible thérapeutique ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en raison de son rôle dans diverses maladies, elle est considérée comme une cible thérapeutique potentielle." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'éphrine A3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications neurologiques et des troubles de développement peuvent survenir en cas d'anomalies." } }, { "@type": "Question", "name": "L'éphrine A3 est-elle impliquée dans des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies d'éphrine A3 sont associées à certains types de cancers, notamment le gliome." } }, { "@type": "Question", "name": "Des troubles cognitifs peuvent-ils être des complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dysfonctionnements de l'éphrine A3 peuvent entraîner des troubles cognitifs sévères." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications implique des traitements symptomatiques et des interventions ciblées." } }, { "@type": "Question", "name": "Y a-t-il des risques de récidive avec l'éphrine A3 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des risques de récidive peuvent exister dans les cas de cancers associés à des anomalies d'éphrine A3." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'éphrine A3 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs génétiques, environnementaux et le mode de vie peuvent influencer le risque d'anomalies." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans les troubles d'éphrine A3 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de troubles neurologiques peuvent augmenter le risque d'anomalies." } }, { "@type": "Question", "name": "Les toxines environnementales affectent-elles l'éphrine A3 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certaines toxines peut perturber l'expression de l'éphrine A3." } }, { "@type": "Question", "name": "Le stress peut-il influencer l'éphrine A3 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affecter la signalisation de l'éphrine A3 et la santé neuronale." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques pour l'éphrine A3 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines variations génétiques peuvent prédisposer les individus à des troubles liés à l'éphrine A3." } } ] } ] }

Sources (10000 au total)

Manhattan Vision Screening and Follow-up Study (NYC-SIGHT): Baseline Results and Costs of a Cluster-Randomized Trial.

To describe the 15-month baseline results and costs of the Manhattan Vision Screening and Follow-up Study, which aims to investigate whether innovative community-based eye health screening can improve... Five-year prospective, cluster-randomized controlled trial.... Individuals aged 40+ years were recruited from public housing buildings in New York City for an eye health screening (visual acuity (VA) with correction, intraocular pressure measurements (IOP), and f... A total of 708 participants were screened; mean age 68.6±11.9 years, female (65.1%), African American (51.8%) and Hispanic (42%). 78.4% (n = 555) failed the eye health screening; 35% (n= 250) had an a... This innovative study in public housing developments targeted high-risk populations, provided access to eye-care, and improved early detection of ocular diseases in New York City. The study has identi...

Survey on pattern of myopia in school children in Hangzhou after the COVID-19 pandemic: a school-based vision screening study.

Myopia is a major health issue around the world. Myopia in children has increased significantly during the COVID-19 pandemic in China, but reports are scarce on the prevalence of myopia following the ... A school-based vision screening study used stratified samplings to collect the vision screening data in school children aged 6-13 from 45 primary schools in Hangzhou. Vision screening data including u... A total of 79,068 screening results (158,136 eyes) were included in the analysis. A substantial myopic shift (approximately -0.30 diopters [D] on average) was found in 2020 and 2021 compared with 2019... Myopia in children has increased rapidly during the COVID-19 pandemic. After the pandemic, the prevalence of myopia in children gradually decreased temporarily and then rebounded. Myopic shift was mor...

Race, poverty, and the lack of follow-up for Arkansas students that fail vision screenings: a cross-sectional study over 7 years.

To analyze rates of follow-up eye care for students that failed school vision screenings over a 7-year period in 238 Arkansas school districts.... In this cross-sectional study, vision screening, demographic, socioeconomic, academic, and eye care provider data were collected. The main outcomes were referral rates, rates of follow-up eye care for... A total of 1,744,805 vision screenings over 7 academic years (2013-2020) were included. The average screening rate was 35.4% across the study years. The screening failure rate ranged from 8.0% to 9.4%... Arkansas children in our study cohort that failed vision screenings had inadequate follow-up eye care. Follow-up rates were associated with several key indicators of socioeconomic status....

Prevalence of myopia and uncorrected myopia among 721 032 schoolchildren in a city-wide vision screening in southern China: the Shantou Myopia Study.

To explore the prevalence and risk factors for myopia and uncorrected myopia in schoolchildren in southern China.... The government-led Shantou Myopia Study was conducted from September 2020 to June 2021. Non-cycloplegic refraction was performed. Uncorrected visual acuity (UCVA) was measured along with presenting vi... This study enrolled 724 828 schoolchildren (77.8% of all schoolchildren in Shantou) from 901 schools. Data from 721 032 schoolchildren (99.5%) were analysed (mean age 11.53±3.13 years, 6-20 years, 373... The overall prevalence of myopia among schoolchildren in Shantou was 51.8%, higher than the national average in China. The proportion of uncorrected myopia is high, especially in primary schools. Our ...

Positive predictive value of dual-modality vision screening in school children 4-7 years of age-a retrospective review in Queensland, Australia.

To report the outcomes and positive predictive value (PPV) of vision screening in schoolchildren 4-7 years of age through the Primary School Nurse Health Readiness Program (PSNHRP) in Queensland, Aust... A retrospective review of schoolchildren who underwent vision screening between January 2017 and December 2020 was conducted. Vision screening was performed through a dual-examination method, using th... Of 185,685 eligible children, 176,164 (94.9%) consented to vision screening, 164,890 (93.6%) consented children underwent vision screening, and of those 12,148 (7.4%) were referred for an eye assessme... The PSNHRP vision screening program showed a high uptake, and the dual screening method was effective in identifying visual abnormalities, with higher PPV when both visual acuity and photoscreener res...

The blinq™ Vision Screener in Detection of Amblyopia and Strabismus.

The blinq (Rebion Inc) is a new screening device designed to directly detect amblyopia and strabismus rather than amblyopia risk factors. We performed an independent assessment of the effectiveness of... Prospective clinical validity analysis of a screening device based on sensitivity and specificity.... Children presenting for examination in the pediatric ophthalmology clinic underwent screening with the blinq before examination by a pediatric ophthalmologist blinded to the screening results. Results... In our cohort of 267 children with an average age of 6.3 years, the sensitivity of the blinq to detect amblyopia or any constant strabismus was 87.5% (78.2%-93.8%) and specificity was 51.3% (43.9%-58.... Our results support use of the blinq as a screening device to detect amblyopia and strabismus in children....

Protocol for an automated, pragmatic, embedded, adaptive randomised controlled trial: behavioural economics-informed mobile phone-based reminder messages to improve clinic attendance in a Botswanan school-based vision screening programme.

Clinic non-attendance rates are high across the African continent. Emerging evidence suggests that phone-based reminder messages could make a small but important contribution to reducing non-attendanc... We will test a new theory-informed SMS and voice reminder message in a national school-based eye screening programme in Botswana. The control will be the standard SMS message used to remind parents/gu... As far as we are aware, only one other study has used behavioural economics to inform the development of reminder messages to be deployed in an African healthcare setting. Our study will use an adapti... ISRCTN 96528723 . Registered on 5 January 2022....

School-Based Delivery of Vision Care in Chicago Public Schools.

In 2012, Chicago Public Schools and the Chicago Department of Public Health partnered together to create the Chicago School-Based Vision Program (CSBVP). This ongoing, city-wide program provides schoo... Descriptive analysis of the program operations from 2012 to 2020, including number of students served and exam findings during 2017-2020, as well as lessons learned and recommendations for reproducing... During its first 8 years, the CSBVP provided eye examinations to over 350,000 students. During the years 2017-2020, this included 126,238 eye exams and provision of eyeglasses to 73,751 students.... The CSBVP is built upon strong community and school relationships. The program offers vision services, equitably, to all students across the district. The lessons learned through the implementation of...

Effectiveness of the Spot Vision Screener using updated 2021 AAPOS guidelines.

To evaluate the Spot Vision Screener according to updated 2021 AAPOS Vision Screening Committee guidelines for instrument-based pediatric vision screen validation.... As part of an IRB-approved ongoing prospective study, children were screened with the Spot prior to a complete examination.... Spot screening was successful in 1,036 of 1,090 children (95%). Forty-eight percent of participants were referred for further screening using the Spot manufacturer guidelines, and 40% of all children ... In our study population, the overall predictive ability of the Spot is good, with a sensitivity of 0.88 and a specificity of 0.78. We recommend specific device refractive referral criteria to maximize...